# EUS-guided Ethanol-lipiodol Ablation of Pancreatic Neuroendocrine Tumor: a Prospective Study

> **NCT01902238** · NA · UNKNOWN · sponsor: **Asan Medical Center** · enrollment: 34 (actual)

## Conditions studied

- Efficacy
- Safety
- Feasibility

## Interventions

- **PROCEDURE:** EUS-guided ethanol-lipiodol mixture ablation

## Key facts

- **NCT ID:** NCT01902238
- **Lead sponsor:** Asan Medical Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-07
- **Primary completion:** 2017-06
- **Final completion:** 2017-08
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2016-12-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01902238

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01902238, "EUS-guided Ethanol-lipiodol Ablation of Pancreatic Neuroendocrine Tumor: a Prospective Study". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01902238. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*